The researchers modified a type of human immune cell — called T lymphocytes, or T cells — to target a molecule called CS1, which is found on more than 95 percent of myeloma cells, and to kill the cells. The researchers grew the modified cells in the lab to increase their numbers and then injected them into an animal model where they again killed human myeloma cells. The findings were published in the journal Clinical Cancer Research…
source : http://www.sciencedaily.com/releases/2014/05/140512124312.htm
source : http://www.sciencedaily.com/releases/2014/02/140204123615.htm
The findings, published in the Journal of Clinical Oncology, come from a study led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James)…
In clinical trials, ibrutinib has often shown exceptional activity in people with chronic lymphocytic leukemia (CLL). …
The physician scientists sought to identify glioblastoma subtype-specific cancer stem cells. Genetic analyses have shown that high-grade gliomas can be divided into four subtypes: proneural, neural, classic and mesenchymal…